2.50
Hdl Handle:
http://hdl.handle.net/10541/66074
Title:
Pharmacological treatment of hypercortisolism.
Authors:
Shalet, Stephen M; Mukherjee, Annice
Abstract:
PURPOSE OF REVIEW: To consider the current status and types of drug therapy aimed at restoring eucortisolaemia in patients with Cushing's syndrome. RECENT FINDINGS: Advances such as laparoscopic adrenalectomy modify the exact placing of drug therapy among the wide variety of therapies available to treat patients with Cushing's syndrome because of different causes; nonetheless, it is now clear that hypercortisolism, per se, if present for any length of time, modifies the future prognosis of the patient, even after cure of the Cushing's syndrome. Thus, early diagnosis and restoration of eucortisolsm are critical. There are three main types of drug therapy: steroidogenesis inhibitors, glucocorticoid antagonists and neuromodulatory compounds. Currently, steroidogenesis inhibitors such as metyrapone and ketaconazole are most commonly the first choice if drug therapy is to be used, but at least for the most common form of Cushing's syndrome, Cushing's disease, the neuromodulatory compounds such as cabergoline show potential. SUMMARY: Pharmacological therapy for Cushing's syndrome remains critically important for normalizing cortisol levels while awaiting the impact of more definitive treatment.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, UK. stephen.m.shalet@man.ac.uk
Citation:
Pharmacological treatment of hypercortisolism. 2008, 15 (3):234-8 Curr Opin Endocrinol Diabetes Obes
Journal:
Current Opinion in Endocrinology, Diabetes, and Obesity
Issue Date:
Jun-2008
URI:
http://hdl.handle.net/10541/66074
DOI:
10.1097/MED.0b013e3282fc7025
PubMed ID:
18438170
Type:
Article
Language:
en
ISSN:
1752-2978
Appears in Collections:
All Christie Publications ; Endocrinology

Full metadata record

DC FieldValue Language
dc.contributor.authorShalet, Stephen M-
dc.contributor.authorMukherjee, Annice-
dc.date.accessioned2009-04-23T15:53:53Z-
dc.date.available2009-04-23T15:53:53Z-
dc.date.issued2008-06-
dc.identifier.citationPharmacological treatment of hypercortisolism. 2008, 15 (3):234-8 Curr Opin Endocrinol Diabetes Obesen
dc.identifier.issn1752-2978-
dc.identifier.pmid18438170-
dc.identifier.doi10.1097/MED.0b013e3282fc7025-
dc.identifier.urihttp://hdl.handle.net/10541/66074-
dc.description.abstractPURPOSE OF REVIEW: To consider the current status and types of drug therapy aimed at restoring eucortisolaemia in patients with Cushing's syndrome. RECENT FINDINGS: Advances such as laparoscopic adrenalectomy modify the exact placing of drug therapy among the wide variety of therapies available to treat patients with Cushing's syndrome because of different causes; nonetheless, it is now clear that hypercortisolism, per se, if present for any length of time, modifies the future prognosis of the patient, even after cure of the Cushing's syndrome. Thus, early diagnosis and restoration of eucortisolsm are critical. There are three main types of drug therapy: steroidogenesis inhibitors, glucocorticoid antagonists and neuromodulatory compounds. Currently, steroidogenesis inhibitors such as metyrapone and ketaconazole are most commonly the first choice if drug therapy is to be used, but at least for the most common form of Cushing's syndrome, Cushing's disease, the neuromodulatory compounds such as cabergoline show potential. SUMMARY: Pharmacological therapy for Cushing's syndrome remains critically important for normalizing cortisol levels while awaiting the impact of more definitive treatment.en
dc.language.isoenen
dc.subjectHypercortisolismen
dc.subjectLaparoscopic Adrenalectomyen
dc.subject.meshAdrenal Cortex Hormones-
dc.subject.meshCushing Syndrome-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshHumans-
dc.subject.meshNeurotransmitter Agents-
dc.titlePharmacological treatment of hypercortisolism.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK. stephen.m.shalet@man.ac.uken
dc.identifier.journalCurrent Opinion in Endocrinology, Diabetes, and Obesityen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.